Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
NCT03054896Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2017
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in Richter's syndrome (RS) (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Complete Response at 3 months. Started Mar 2017; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT03054896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054896.